Roche Group’s Genentech said late Tuesday the Food and Drug Administration has approved its Tecentriq immunotherapy medicine for the treatment of certain types of lung cancer. Tecentriq may treat lung cancer by working with the immune system and targeting a protein. More studies are evaluating Tecentriq alone and in combination with other medicines, the South San Francisco, Calif., company said in a statement.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News